Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 9/20 | 0.36 |
| ▸ | FABP3 | P05413 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexanoate SCHEMBL19406559 | 0.95 | FABP3 (0.42) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Succinic Acid SCHEMBL18575091 | 0.95 | CA1 (0.40) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Octanoic Acid SCHEMBL3125477 | 0.94 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Butyric Acid SCHEMBL507692 | 0.94 | FFAR3 (0.42) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Palmitic Acid SCHEMBL28783480 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Palmitic Acid SCHEMBL28783450 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Dodecanoate SCHEMBL28783501 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Palmitic Acid SCHEMBL28783479 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Myristic Acid SCHEMBL29183500 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 | |
| Palmitic Acid SCHEMBL28783485 | 0.91 | FABP3 (0.44) | CA1MEN1HSP90AA1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674121-B2 | Process for the production of benzofurans | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| EP-2435398-B1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| US-20120065411-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI (FR) | 2012-03-15 | — | — | US | disclosed |
| WO-2010136500-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065411-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | CYP2F1, CYP2B6, CYP4F2 | CA1 3100/4885MEN1 4303/4885HSP90AA1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.